The first patient in a study of the In.Pact Admiral drug-coated balloon as a treatment for failing arteriovenous fistulas in patients with end-stage renal disease has been enrolled by Medtronic. The study, which will randomize 330 patients to be treated with either the device or standard percutaneous transluminal angioplasty, has a primary safety endpoint of 30-day serious adverse events and a primary efficacy endpoint of six-month patency of dialysis fistulas.
Study begins for Medtronic's drug-coated balloon for end-stage renal disease
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.